Company TxCell

Equities

TXCL

FR0010127662

Biotechnology & Medical Research

Business Summary

Managers

Members of the board

Share class

Company contact information

Sector

Sector Bio Therapeutic Drugs

Real-time Euronext Paris Other stock markets			5-day change	1st Jan Change
- ^EUR	-.--%		-.--%	+67.53%

TxCell is a biotechnology company which develops platforms for innovative customized cell immunotherapies from regulatory T cells (Treg) for the treatment of severe chronic inflammatory, autoimmune diseases and transplant rejection.

TxCell is developing a platform for genetically modified T-cells, the CAR-Tregs. TxCell plans to release preclinical proof-of-concept data in 2017 and start a first clinical study by the end of 2018.

Managers	Title	Age	Since
Caroline Courme IRO	Public Communications Contact	-	29/02/16
Pierre Desreumaux PRN	Corporate Officer/Principal	-	-
Matthieu Allez PRN	Corporate Officer/Principal	-	-
Bernard Malissen PRN	Corporate Officer/Principal	-	-
Pierre Heimendinger PRN	Corporate Officer/Principal	61	-

Members of the board	Title	Age	Since
Duncan Mckay CHM	Chairman	-	11/02/19

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	23,195,394	1,045,009 ( 4.505 %)	0	4.505 %

Sangamo Therapeutics France SAS

Les Cardoulines HT1 Allée de la Nertière

06560, Valbonne

+33 4 97 21 83 00

http://txcell.com/

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-1.17%	104B
REGENERON PHARMACEUTICALS, INC.	+2.87%	97.47B
ARGENX SE	+2.13%	22.25B
BIONTECH SE	-14.77%	21.68B
GENMAB A/S	-8.79%	18.2B
WUXI APPTEC CO., LTD.	-39.98%	17.02B
BEIGENE, LTD.	-13.21%	16.36B
NEUROCRINE BIOSCIENCES, INC.	+8.55%	14.39B
SAREPTA THERAPEUTICS, INC.	+35.75%	12.37B

Bio Therapeutic Drugs